Full-Time

Clinical Lab Technologist I/II

Confirmed live in the last 24 hours

Adaptive Biotechnologies

Adaptive Biotechnologies

501-1,000 employees

Decodes immune cell receptors for diagnostics

Compensation Overview

$26.87 - $40.34/hr

+ Equity Grant

Entry, Junior, Mid, Senior

No H1B Sponsorship

Seattle, WA, USA

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Requirements
  • Must meet ONE of the following: Bachelor’s or higher in medical technology or laboratory science from an accredited institution, Bachelor’s or higher in one of the chemical or biological sciences from an accredited institution + 6 months of high-complexity molecular experience and/or training in a clinical laboratory (holding a CLIA Certificate of Compliance/Accreditation)
  • Molecular biology skills (e.g. DNA Extraction, Purification, PCR, qPCR, next-generation DNA sequencing) and related technical knowledge.
  • Experience working with human specimens (e.g. blood, tissues and/or cells) and biohazardous material.
  • Strong communication and interpersonal skills, ability to collaborate across teams and disciplines.
  • Bachelor’s or higher in medical technology or laboratory science, chemical science, or biological science from an accredited institution (for Clinical Lab Technologist II).
  • Minimum of 1 year of experience and/or training in a clinical laboratory (holding a CLIA Certificate of Compliance/Accreditation) meeting the definition of “high-complexity” (for Clinical Lab Technologist II).
  • Minimum of 3 years of pertinent molecular laboratory experience (for Clinical Lab Technologist II).
Responsibilities
  • Performs and provides general support for DNA extractions, PCR amplification, or high-throughput sequencing assays on DNA libraries in accordance with standard laboratory processes and procedures.
  • Operates and maintains laboratory equipment such as liquid handling robotics and DNA sequencers.
  • Completes tasks as assigned (e.g. routine clinical or research sample processing, validations, reagent QC runs, or special projects) accurately while following strict methodologies.
  • Provides guidance to entry-level staff.
  • Performs training and/or competency assessments for Clinical Laboratory Technician/Technologist team members on high complexity molecular methods (Clinical Lab Technologist II).
  • Performs protocols under compliance with regulatory agencies, models appropriate clinical, regulatory and safety practices.
  • Makes decisions that impact quality, timeliness, and effectiveness of the team.
  • Resolves basic problems that may involve uncommon variations of issues.
  • Identifies and uses up to date, accurate information for problem solving and analysis.
  • Ensures compliance with lab regulatory agencies (GxP, FDA, ISO).
  • Keeps accurate and detailed records for all workflows following Good Documentation Practices.
Desired Qualifications
  • ASCP(MB) certification
  • Specialized knowledge and skills: Experience in a clinical, high-throughput environment is preferred.
  • Working knowledge of laboratory terminology, equipment, and supplies.
  • Competent in laboratory automation and demonstrated laboratory best practices.
  • Experience working within an electronic Laboratory Information Management System.
  • Self-motivated and can work independently, with minimal supervision, while also working as part of a team environment in a dynamic organization. Strong interpersonal and communication skills, both written and spoken.
Adaptive Biotechnologies

Adaptive Biotechnologies

View

Adaptive Biotechnologies focuses on using the immune system to improve disease diagnosis and treatment. The company decodes genetic information from immune cell receptors, which are essential for the immune system's ability to identify and respond to diseases. One of their key projects is the ImmuneRACE study, which analyzes blood samples and swabs from participants to understand how the immune system reacts to COVID-19. This research aims to enhance diagnostics, treatments, and vaccines for the virus. Adaptive Biotechnologies uses advanced data algorithms to analyze immune cell genetics and generates revenue through partnerships with pharmaceutical companies, licensing technology, and offering diagnostic services. Their goal is to advance healthcare by leveraging immune system data to develop better therapies and diagnostic tools.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Seattle, Washington

Founded

2009

Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from equity firms indicate strong market confidence and growth potential.
  • Participation in high-profile conferences suggests potential for new partnerships and collaborations.
  • Winning Workplace of the Year Award highlights strong company culture and employee satisfaction.

What critics are saying

  • Increased competition from startups like Adaptive with $20 million funding for AI models.
  • New CFO may lead to strategic shifts impacting financial stability or direction.
  • Focus on COVID-19 research may face reduced demand as pandemic attention wanes.

What makes Adaptive Biotechnologies unique

  • Pioneers in immune-driven medicine, leveraging adaptive immune system for diagnostics and treatment.
  • FDA-authorized clonoSEQ test for minimal residual disease in select blood cancers.
  • Specializes in decoding genetic information of immune cell receptors for better diagnostics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-3%

2 year growth

2%
ETF Daily News
Mar 16th, 2025
Arizona State Retirement System Invests $179,000 in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Arizona State Retirement System invests $179,000 in Adaptive Biotechnologies Co. (NASDAQ:ADPT).

GlobeNewswire
Jan 2nd, 2025
Adaptive Biotechnologies To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.Adaptive Biotechnologies’ management is scheduled to present on Tuesday, January 14th at 5:15 p.m. Pacific Time / 8:15 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.About Adaptive BiotechnologiesAdaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease

MarketBeat
Dec 10th, 2024
Jacobs Levy Equity Management Inc. Makes New $736,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Jacobs Levy Equity Management Inc. makes new $736,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT).

Adaptive Biotechnologies
Dec 3rd, 2024
Press Release Details

"We are inspired to see clonoSEQ MRD testing featured in a record-breaking number of studies at this year's ASH Annual Meeting," said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies.

ETF Daily News
Sep 29th, 2024
Canada Pension Plan Investment Board Makes New $98,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Canada Pension Plan Investment Board makes new $98,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT).